trending Market Intelligence /marketintelligence/en/news-insights/trending/5N4mkD5X0_UjAwOP0M_f-g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

OncoCyte to acquire Insight Genetics for $12M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

OncoCyte to acquire Insight Genetics for $12M

OncoCyte Corp. agreed to acquire private molecular diagnostics company Insight Genetics Inc. for about $12 million in a cash and stock deal.

OncoCyte will pay $7 million in cash and common shares worth $5 million to the Nashville, Tenn.-based private company that specializes in the discovery, development and commercialization of molecular diagnostics that detect specific cancer biomarkers in triple negative breast cancer and lung cancer to guide effective diagnosis, treatment and monitoring of cancer.

Under the agreement, Alameda, Calif.-based OncoCyte will also pay a share of up to 10% of net revenues collected for current Insight Genetics pharma service offerings for 10 years and a tiered revenue share percentage of net collected revenues through the end of the lifecycle if certain new cancer tests are developed using Insight Genetics technology.

Additionally, OncoCyte has agreed to pay up to $6 million in any combination of cash or OncoCyte shares, subject to certain milestones.

Completion of the deal is subject to closing conditions including approval from Insight Genetics' shareholders.